Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 18Gynecologic 7Thoracic 4Genitourinary 3Endocrine 3Dermatologic 3Sarcoma 2CNS 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Breast 1

Conditions

Uveal Melanoma 2Melanoma 2

Interventions

Ipilimumab 101pembrolizumab 94Nivolumab 87Cyclophosphamide 69fludarabine phosphate 55aldesleukin 52Interleukin-2 39Dacarbazine 35Vemurafenib 31fludarabine 30trametinib 29dabrafenib 29Temozolomide 28Whole-Body Irradiation 21Aminolevulinic Acid 21Carboplatin 20CTLA-4 Antigen 20Bevacizumab 20Radiotherapy 19Peripheral Blood Stem Cell Transplantation 19Radiosurgery 18Tacrolimus 17Mycophenolic Acid 17Paclitaxel 16HhAntag691 163-ingenyl angelate 16Busulfan 15Introns 14Antilymphocyte Serum 14encorafenib 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × aflibercept × Dermatologic × Clear all
NCT03712904 2025-09-24

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Thomas Jefferson University

Phase 2 Terminated
3 enrolled 9 charts
Dermatologic

Uveal Melanoma

NCT01258855 2019-05-10

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
84 enrolled 13 charts
Dermatologic

Melanoma

NCT00450255 2018-05-24

VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 7 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡